Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...
First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results